Connor Clark & Lunn Investment Management Ltd. Acquires 19,554 Shares of InfuSystem Holdings, Inc. $INFU

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 38.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,772 shares of the company’s stock after purchasing an additional 19,554 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.33% of InfuSystem worth $435,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of INFU. Bank of New York Mellon Corp grew its stake in InfuSystem by 4.7% in the 1st quarter. Bank of New York Mellon Corp now owns 95,471 shares of the company’s stock worth $514,000 after buying an additional 4,252 shares in the last quarter. CWM LLC raised its position in shares of InfuSystem by 1,160.1% during the 2nd quarter. CWM LLC now owns 4,826 shares of the company’s stock valued at $30,000 after buying an additional 4,443 shares in the last quarter. Bard Associates Inc. lifted its holdings in shares of InfuSystem by 8.8% during the 1st quarter. Bard Associates Inc. now owns 61,600 shares of the company’s stock worth $331,000 after acquiring an additional 5,000 shares during the last quarter. Jump Financial LLC purchased a new position in InfuSystem in the first quarter worth $58,000. Finally, Williams & Novak LLC bought a new position in InfuSystem in the second quarter valued at $77,000. 71.13% of the stock is owned by hedge funds and other institutional investors.

InfuSystem Stock Down 0.6%

Shares of NYSE:INFU opened at $9.22 on Friday. The stock has a market capitalization of $187.50 million, a P/E ratio of 153.69 and a beta of 1.80. The stock’s 50-day moving average price is $9.94 and its 200-day moving average price is $8.01. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12-month low of $4.61 and a 12-month high of $11.04.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Zacks Research lowered InfuSystem from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Lake Street Capital started coverage on InfuSystem in a report on Monday, September 22nd. They set a “buy” rating and a $15.00 price objective on the stock. Finally, Roth Capital reaffirmed a “buy” rating and issued a $14.00 target price (up previously from $13.00) on shares of InfuSystem in a research note on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $14.50.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.